MSB 3.50% $1.33 mesoblast limited

Regenexx are competitors. The difference is that they inject the...

  1. 3,703 Posts.
    lightbulb Created with Sketch. 48
    Regenexx are competitors. The difference is that they inject the patient with his own stem cells. This process is not FDA approved. In fact Regenexx are in fighting the FDA, on the basis that it is a surgical procedure and therefore not an FDA issue. So there has not been any trials that prove their assertions about efficacy. In fact you will find very little authoritive unbiased imformation about Regenexx. So they have a vested interest in baggging MSB. Never the less, I would like a clinician to evaluate the article by them.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.33
Change
0.045(3.50%)
Mkt cap ! $1.518B
Open High Low Value Volume
$1.30 $1.35 $1.30 $2.885M 2.183M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.32
 

Sellers (Offers)

Price($) Vol. No.
$1.33 7070 1
View Market Depth
Last trade - 16.10pm 06/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.